Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
$1.53
-7.8%
$1.55
$0.19
$2.65
$26.93M3.081.39 million shs36,047 shs
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$0.30
-1.3%
$0.34
$0.29
$0.71
$55.44M0.8411,994 shs12,563 shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$4.73
-1.9%
$4.98
$0.13
$1.04
$91.09M1.581.05 million shs7,088 shs
WHWK
Whitehawk Therapeutics
$1.95
+0.5%
$0.00
$1.21
$3.81
$91.39M0.55113,502 shs115,911 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
+2.47%+1.84%+23.88%+37.76%-46.96%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.00%-6.16%-7.98%-5.69%-52.01%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
+2.77%+7.11%+1.26%-17.89%+1,990.20%
WHWK
Whitehawk Therapeutics
-3.48%+4.86%+193,999,900.00%+193,999,900.00%+193,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/AN/AN/AN/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
WHWK
Whitehawk Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
0.00
N/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.00
N/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
2.00
Hold$5.005.71% Upside
WHWK
Whitehawk Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/A$0.48 per shareN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$9.14M6.07N/AN/A($0.01) per share-29.60
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
WHWK
Whitehawk Therapeutics
$25.98M3.54N/AN/A$2.12 per share0.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
-$21.12M-$0.02N/AN/A-115.14%N/A-60.81%N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%8/6/2025 (Estimated)
WHWK
Whitehawk Therapeutics
-$63.69M$0.1612.19N/A99.42%-56.73%-48.68%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
WHWK
Whitehawk Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
N/A
3.01
3.01
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/A
0.60
0.50
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27
WHWK
Whitehawk Therapeutics
N/A
18.95
18.95

Institutional Ownership

CompanyInstitutional Ownership
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
13.36%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.03%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%
WHWK
Whitehawk Therapeutics
52.08%

Insider Ownership

CompanyInsider Ownership
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
30.24%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
47.68%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
WHWK
Whitehawk Therapeutics
49.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hillstream BioPharma, Inc. stock logo
HILS
Hillstream BioPharma
117.60 million12.28 millionNot Optionable
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
90187.31 million96.34 millionNo Data
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionOptionable
WHWK
Whitehawk Therapeutics
4047.11 million23.60 millionN/A

Recent News About These Companies

Media Sentiment Over Time

Hillstream BioPharma stock logo

Hillstream BioPharma NASDAQ:HILS

$1.53 -0.13 (-7.83%)
As of 07/24/2025

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

PyroGenesis Canada stock logo

PyroGenesis Canada NASDAQ:PYRGF

$0.30 0.00 (-1.33%)
As of 02:09 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$4.73 -0.09 (-1.87%)
As of 07/24/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Whitehawk Therapeutics NASDAQ:WHWK

$1.95 +0.01 (+0.52%)
As of 04:00 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.